Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2023 | Story André Damons | Photo Charl Devenish
Prof Mokgadi Matlakala
Prof Mokgadi Matlakala, Academic Chairperson of the Department of Health Studies at UNISA and Deputy Chairperson of the Forum for University Deans in South Africa (FUNDISA), was the keynote speaker and acknowledged the contribution of nurses and the courage to continue to advocate for improved health and healthcare.

Nurses serve with pride, and they should be protected, valued, and respected.

This was the recurring thought from speakers at the University of the Free State (UFS) School of Nursing’s International Nurses Day celebrations.

“We celebrate this day to highlight the importance of nurses in the healthcare services, and to honour our heroes – us being the heroes as well,” said keynote speaker Prof Mokgadi Matlakala, Academic Chairperson of the Department of Health Studies at UNISA and Deputy Chairperson of the Forum for University Deans in South Africa (FUNDISA). “We acknowledge the contribution of nurses and the courage to continue to advocate for improved health and healthcare – and this amid the challenges confronting us.”  

Prof Matlakala said the theme of the day, “Our Nurses. Our Future”, comes at a very critical time for the nursing profession, given the circumstances following the COVID-19 pandemic, and the ongoing transformation needed in nursing education, particularly in South Africa. 

International Nurses Day is celebrated annually on 12 May, and this year the UFS School of Nursing also hosted a tree-planting to commemorate nurses who lost their lives during the pandemic. Several other activities, including an Amazing Race, outdoor events, and stalls portrayed nursing services in various contexts. 

Prof Matlakala said the day also serves as a way of sharing ideas about changes taking place in nursing, and imagining a nurse of the future, both in practice and academia. “In the African context, it is important for us to reflect and understand who our nurses are, where are they, and where have they been trained.”

World mistakenly took nurses for granted

“Today we have an opportunity to celebrate ourselves as nurses, and I encourage you to acknowledge the good work you are doing. And I include the student nurses as well, because they are our future.”

Prof Matlakala said during the pandemic the world mistakenly took nurses for granted. “They treated us as invisible, and as an inexhaustible resource,” she said, outlining areas such as illness among nurses, fear of the pandemic, death, work overload, and unprecedented changes in nursing environments and nursing education as areas where nurses were “taken for granted as superheroes”.

“The pandemic is over, but the question is: Did the nurses receive any counselling after surviving the pandemic? Did they get special leave to rest? In the nursing practice it is business as usual. In nursing education institutions, they are speaking of catching up on the time lost during the pandemic. Nobody is thinking of exhaustion as a non-communicable disease. Yet, many of our nurses are suffering from exhaustion both mentally and physical. It is thus important that we advocate for wellness for our nurses.”

Protect. Respect. Value

Prof Matlakala said protecting nurses relates to how the government or health system can address the growing nursing shortage and provide positive practice environments, especially with regard to safety in the workplace. She also said the ongoing shortage of nurses is a pandemic that is felt across the globe.

Her message to future nurses is that the profession needs nurses who will be available to confront the many challenges nurses are experiencing. “You need to be assertive and take control of your professional status despite the problems we are hearing. One of the values that we need to have is a positive attitude, which means we need to focus on solutions, not only on problems.”

Celebrating the impact of nursing services

Prof Gert van Zyl, Dean of the UFS Faculty of Health Sciences, welcomed guests and said International Nurses Day celebrates the impact of nursing services in providing high-quality healthcare to patients and improving their overall wellbeing. 

“Nurses play a critical role in the healthcare system, providing care, support, and education to patients and their families. Thank you for your dedication and passion for your profession,” Prof Van Zyl said. “Thank you for all the sacrifices you made to provide the highest level of care and support to people in need in the recent COVID-19 time. Moreso, your contribution to the healthcare industry is immeasurable. We are grateful for everything you do and have done. Keep up the excellent work.”

He added that he believes professional nurses are motivated by many factors, including three main ones: “A desire to help others, a sense of purpose, and the satisfaction of making a difference in people’s life. To motivate nurses for the future, it is important to recognise their achievements, to support them, and to provide opportunities for development and growth.” 

Dr Jeanette Sebaeng, Head of the School of Nursing, said she is privileged to be part of this “very sacred” profession. “I had an opportunity to see life for the first time. I had an opportunity to close someone’s eyes for the first time. I don’t think I would be anything else, even in the next life, other than a nurse.” 

She said when 2020 was declared the Year of the Nurse and Midwife, by year-end the meaning had become grim. “We did not expect that it would be our year in that manner. We lost close to 300 nurses in South Africa due to COVID-19. Even after losing our colleagues, here we are, still strong. That is resilience, and for that I salute you.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept